Back to search

Germany· DE-A57-5e4953fbd5a44a7b

Bupivacain Mit Epinephrin Jenapharm

A medicinal product containing bupivacaine hydrochloride, epinephrine bitartrate, registered in Germany by Mibe Gmbh Arzneimittel.

Checked against EMA Article 57 (European Union) on

Informational only — not a medical device.

SOURCE REGISTER · DEEMA Article 57 (European Union)normalisedBupivacain Mit Epinephrin JenapharmATC—REGISTER NO.DE-A57-5e4953fbd5a44a…PACKS LISTED0CHECKEDJuly 8, 2026

The record

At a glance

EMA Article 57 (European Union)
Active substance
Bupivacaine Hydrochloride, Epinephrine Bitartrate
Manufacturer
Mibe Gmbh Arzneimittel
Country
Germany (DE)
ATC code
—
Reimbursed
Not published by this register
Source register
EMA Article 57 (European Union)
Last checked
July 8, 2026

Packs & prices · 0

No packs listed by the register for this record.

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of EMA Article 57 (European Union). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/188f2448-1561-44f4-a7ac-ce4c119b85f9
GET /v1/drugs/188f2448-1561-44f4-a7ac-ce4c119b85f9?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "pzn": null,
  "route": "Epidural Use ,Intradermal Use ,Intrathecal Use ,Subcutaneous Use",
  "source": "ema_art57_de",
  "ma_number": null,
  "substance": "Bupivacaine Hydrochloride, Epinephrine Bitartrate",
  "atc_from_source": null,
  "authorisation_country": "Germany"
}

See everything about bupivacaine hydrochloride, epinephrine bitartrate.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.